Similar Papers

Paper Title
Journal
Date
Author
Meta-Analysis of EGFR Kinase Inhibitors: Not Always Greater Than the Sum of Its Parts
S Cardarella ... B E Johnson
JNCI Journal of the National Cancer Institute | VOL. 105
S Cardarella, et. al.S Cardarella ... B E Johnson
17 Apr 2013
Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?
Assunta Sgambato ... Cesare Gridelli
Journal of thoracic disease | VOL. 6
Assunta Sgambato, et. al.Assunta Sgambato ... Cesare Gridelli
25 Jun 2014
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
L.E Hendriks ... M Reck
Annals of Oncology | VOL. 34
L.E Hendriks, et. al.L.E Hendriks ... M Reck
23 Jan 2023
Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS)
Y Wu ... M Fukuoka
Journal of Clinical Oncology | VOL. 27
Y Wu, et. al.Y Wu ... M Fukuoka
20 May 2009
View more papers

More From: EJC Supplements

Paper Title
Journal
Date
Author
Immunotherapies in ovarian cancer
Elena García-Martínez ... J Alejandro Pérez-Fidalgo
EJC Supplements | VOL. 15
Elena García-Martínez, et. al.Elena García-Martínez ... J Alejandro Pérez-Fidalgo
01 Aug 2020
Anti-angiogenic therapy for ovarian cancer
Yolanda García García ... Clara Martínez Vila
EJC Supplements | VOL. 15
Yolanda García García, et. al.Yolanda García García ... Clara Martínez Vila
01 Aug 2020
Editorial board
-
EJC Supplements | VOL. 13
--
01 Dec 2015
Biosimilars: Extrapolating the evidence. A roundtable discussion
Bradley J Monk ... George Somlo
EJC Supplements | VOL. 13
Bradley J Monk, et. al.Bradley J Monk ... George Somlo
01 Dec 2015
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.